Loading
A phase 2 trial of Plicamycin in Lung cancer, Oesophageal cancer, Mesothelioma and Breast cancer, run by National Cancer Institute (NCI), recorded as terminated on the registry.
Mithramycin for Lung, Esophagus, and Other Chest Cancers is a phase 2 interventional study registered as NCT01624090 by National Cancer Institute (NCI), with 16 participants recorded, started 2012-09-06 and due to reach its primary completion in 2019-08-20. Interventions recorded: Mithramycin. Conditions recorded: Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer.
Linked to the drug Plicamycin because the registry names it among its interventions and Lung cancer, Oesophageal cancer, Mesothelioma and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Oesophageal cancer and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/